LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.
ATM
DNA damage
homologous recombination repair
non-Hodgkin's lymphoma
transcription-coupled nucleotide excision repair
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
12 06 2023
12 06 2023
Historique:
medline:
14
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Despite advances in therapies treating non-Hodgkin's lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL. Here we investigated the mechanism of action (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in both
Identifiants
pubmed: 37306526
pii: 28454
doi: 10.18632/oncotarget.28454
pmc: PMC10259262
doi:
Substances chimiques
acylfulvene
0
Bortezomib
69G8BD63PP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
597-611Références
Cancers (Basel). 2021 Oct 23;13(21):
pubmed: 34771492
Leukemia. 2008 Jan;22(1):179-85
pubmed: 17898787
Cell Res. 2008 Jan;18(1):73-84
pubmed: 18166977
Oncol Rep. 2022 Jun;47(6):
pubmed: 35506458
Mutagenesis. 1991 Nov;6(6):449-53
pubmed: 1800891
Sci Rep. 2019 Dec 2;9(1):18062
pubmed: 31792264
DNA Repair (Amst). 2015 Nov;35:126-36
pubmed: 26519826
DNA Repair (Amst). 2002 Dec 5;1(12):1027-38
pubmed: 12531012
Leukemia. 2022 Jan;36(1):197-209
pubmed: 34304248
Nucleic Acids Res. 2015 Mar 31;43(6):3154-66
pubmed: 25753674
J Zhejiang Univ Sci B. 2021 Jan 15;22(1):47-62
pubmed: 33448187
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Mutat Res. 1982 Aug;95(2-3):427-40
pubmed: 6889677
Leukemia. 2018 Jan;32(1):111-119
pubmed: 28588253
Clin Cancer Res. 2004 Aug 15;10(16):5604-13
pubmed: 15328203
Haematologica. 2012 Jan;97(1):47-55
pubmed: 21993670
Nucleic Acids Res. 2020 Feb 20;48(3):e14
pubmed: 31832687
Nat Biotechnol. 2017 Apr 11;35(4):314-316
pubmed: 28398314
Nat Commun. 2019 Jan 8;10(1):87
pubmed: 30622252
PLoS One. 2012;7(6):e40342
pubmed: 22768280
J Pers Med. 2022 Mar 01;12(3):
pubmed: 35330376
Cell Mol Life Sci. 2009 Mar;66(6):981-93
pubmed: 19153658
Clin Cancer Res. 2003 Jul;9(7):2817-25
pubmed: 12855662
Hematol Oncol. 2021 Dec;39(5):605-615
pubmed: 34651869
J Biol Chem. 2004 Sep 17;279(38):39584-92
pubmed: 15269203
Blood. 2002 Jan 1;99(1):238-44
pubmed: 11756177
Cell Res. 2008 Jan;18(1):85-98
pubmed: 18157157
Blood Adv. 2021 Jan 12;5(1):185-197
pubmed: 33570628
DNA Repair (Amst). 2023 Feb;122:103433
pubmed: 36566616
Cancer Treat Rev. 2020 Nov;90:102090
pubmed: 32892059
Chem Biol. 2014 Mar 20;21(3):398-407
pubmed: 24508195
Blood Adv. 2020 Jul 14;4(13):2927-2938
pubmed: 32598477
Transl Cancer Res. 2013 Jun;2(3):130-143
pubmed: 24000320
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15
pubmed: 35561299
Cancer Res. 2012 Jul 15;72(14):3499-511
pubmed: 22802077
Oncology (Williston Park). 2022 Jun 10;36(6):366-375
pubmed: 35723942
Mol Cancer Res. 2017 Aug;15(8):967-972
pubmed: 28634224
Med Sci (Basel). 2021 Jan 30;9(1):
pubmed: 33573146
Am J Hematol. 2021 Mar 1;96(3):302-311
pubmed: 33306213
Cancer Cell. 2019 Sep 16;36(3):237-249.e6
pubmed: 31447348
Mol Cancer Ther. 2010 Feb;9(2):347-57
pubmed: 20124459
Chin Med J (Engl). 2020 Dec 8;134(3):253-260
pubmed: 33323828
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
J Hematol Oncol. 2015 Apr 22;8:39
pubmed: 25895498